We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Emergency Reversal of Novel Oral Anticoagulants Help Is on the Way

Stephan A. Mayer, MD1
[+] Author Affiliations
1Icahn School of Medicine at Mount Sinai, New York, New York
JAMA Neurol. 2016;73(2):155-156. doi:10.1001/jamaneurol.2015.3884.
Text Size: A A A
Published online


Nothing should strike terror in the heart of a neurologist or emergency medicine physician more than a patient with an intracranial hemorrhage while receiving novel oral anticoagulant (NOAC) therapy. The problem, of course, is that until recently, there have been no proven effective agents for emergency reversal of direct factor Xa antagonists and direct thrombin inhibitors. The current state of the art for reversing warfarin and other vitamin K antagonists is use of a 4-factor prothrombin complex concentrate.1 For the NOACs, we have had no analogous “silver bullet.” In recent trials comparing various forms of anticoagulation for atrial fibrillation, NOAC-associated intracranial hemorrhage has been associated with mortality rates of 45% to 67%.24 With no evidence to guide treatment decisions, clinicians on the front lines have been forced to improvise. Fresh frozen plasma; 3-factor, 4-factor, and activated prothrombin complex concentrates PCCs; recombinant factor VIIa; and cryoprecipitate have all been tried, alone or in combination, in an attempt to do something, anything. Adding to the chaos, there have been no data systematically evaluating the potential efficacy of these treatments.

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles